Good Week for Gilead’s Hepatitis-C Treatments, UBS Says
November 21, 2014 at 13:11 PM EST
UBS strategist Matthew Roden and team note that it was another good week Gilead Sciences’ (GILD) hepatitis-C treatments: AP Scripts for Gilead’s Harvoni during the week ending November 14 were released today with total scripts of 3,606, up +37% w/w. These data are strong in the context of feedback at AASLD that Harvoni Rx are [...]
